Skip to main content
Clinical Trials/NCT06598098
NCT06598098
Recruiting
N/A

MAMA Tot - Healthy Weight Parallel Study

East Carolina University1 site in 1 country268 target enrollmentOctober 18, 2021

Overview

Phase
N/A
Intervention
Not specified
Conditions
Pregnancy Related
Sponsor
East Carolina University
Enrollment
268
Locations
1
Primary Endpoint
1 month Infant non-HDL
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

The overall objective of this proposal is to conduct a longitudinal prospective study of healthy pregnant women and their offspring to determine which antenatal maternal exercise mode(s) will have the greatest impact on maternal and infant cardiometabolic health. This information may lead to modified clinical practice recommendations that improve health in childhood and possibly beyond. This randomized controlled trial will recruit 268 healthy pregnant women randomized to an exercise intervention (aerobic exercise, resistance exercise, aerobic and resistance exercise) or to no exercise (usual care); their infants will be measured at 1, 6, and 12 months of age. This rigorous design will test our central hypothesis that aerobic and resistance exercise and resistance exercise training during pregnancy will, in healthy weight BMI (HW) women, improve maternal and offspring cardiometabolic outcomes to a greater extent than AE alone. We will test this hypothesis with two specific aims:

Aim 1. Determine the influence of different exercise modes during HW pregnancy on infant cardiometabolic health and growth trajectories. Hypothesis: AE, RE, and AERE by HW pregnant women will improve offspring neuromotor and cardiometabolic measures at 1, 6, and 12 months postpartum (e.g. decreased % body fat, BMI z-score, heart rate, non-HDL, and C-Reactive Protein (CRP); increased insulin sensitivity) compared to infants of HW pregnant women that do not exercise; AERE and RE will have the greatest impact on improving infant measures.

Aim 2. Determine the most effective exercise mode in HW pregnancy on improving maternal cardiometabolic health outcomes. Hypothesis: AE, RE, and AERE by HW pregnant women will improve both maternal cardiometabolic health measures (e.g. decreased BMI z-score, non-HDL, % body fat, HR, weight gain) across pregnancy (16 to 36 weeks gestation) and overall pregnancy outcomes (e.g. lower incidence of gestational diabetes, pre-eclampsia, hypertension during gestation) compared to HW pregnant women that do not exercise; AERE and RE will have the greatest impact on improving maternal health measures, with the AERE group having the highest compliance.

The proposed innovative study will be the first to provide a critical understanding of the influence of antenatal exercise modes upon the cardiometabolic health and growth trajectories of offspring who may be at increased risk of poor outcomes. This work will have a significant impact on reducing the cycle of OB and CVD, potentially providing the earliest and most efficacious intervention to attenuate or prevent OB and CVD in the next generation.

Registry
clinicaltrials.gov
Start Date
October 18, 2021
End Date
August 30, 2027
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Linda May

Associate Professor; Dept. Chair

East Carolina University

Eligibility Criteria

Inclusion Criteria

  • Age: 18 to 40 years old
  • BMI 18.5 to 24.4
  • Pregnancy: Singleton; ≤ 16 weeks gestation
  • Clearance by Obstetric provider for exercise

Exclusion Criteria

  • Age: ≤ 17.9 or ≥ 41 years of age
  • Multi fetal pregnancy
  • Obstetric Provider does not provide clearance for exercise
  • Unable or Unwilling to provide consent
  • Inability to communicate with members of study team, despite use of interpreter
  • Medical Conditions (e,g. HIV/Aids, Cancer, Type 1 or 2 Diabetes, Untreated Hypertension, Thyroid Disorders)
  • Use of tobacco products, alcohol, recreational drugs, or medications (oral hypertensive, insulin)
  • Unable to provide phone or email contact

Outcomes

Primary Outcomes

1 month Infant non-HDL

Time Frame: 1 month

non-HDL measures from venipuncture

6 month Infant non-HDL

Time Frame: 6 months

non-HDL measures from venipuncture

12 month Infant non-HDL

Time Frame: 12 months

non-HDL measures from venipuncture

1 month infant BMI z-score

Time Frame: 1 month

BMI normalized

6 month infant BMI z-score

Time Frame: 6 months

BMI normalized

12 month infant BMI z-score

Time Frame: 12 months

BMI normalized

Enrollment (8-13wks) Maternal fasting non-HDL

Time Frame: enrollment (~8-13 wks gestation)

non-HDL measured from venipuncture

36wk Maternal fasting non-HDL

Time Frame: 36wks gestation

non-HDL measured from venipuncture

1 month Maternal fasting non-HDL

Time Frame: 1 month postpartum

non-HDL measured from venipuncture

6 month Maternal fasting non-HDL

Time Frame: 6 months postpartum

non-HDL measured from venipuncture

Adverse Pregnancy Outcomes

Time Frame: At delivery

Presence or absence of Adverse Pregnancy outcomes (preterm birth, gestational diabetes \[GDM\], preeclampsia, hypertension)

12 month Maternal fasting non-HDL

Time Frame: 12 months postpartum

non-HDL measured from venipuncture

Secondary Outcomes

  • 12 month Postpartum Maternal Resting Blood Pressure(12 months postpartum)
  • Maternal Gestational Weight Gain (GWG)(At delivery)
  • 16wk Maternal Body Fat %(16wks gestation)
  • 1 month infant Resting Heart Rate(1 month)
  • 6 month infant Resting Heart Rate(6 months)
  • 12 month infant Resting Heart Rate(12 months)
  • 1 month infant Resting Blood Pressure(1 month)
  • 6 month infant Resting Blood Pressure(6 months)
  • 12 month infant Resting Blood Pressure(12 months)
  • 1 month infant Body Fat %(1 month)
  • 6 month infant Body Fat %(6 months)
  • 12 month infant Body Fat %(12 months)
  • 1 month infant % Muscle Mass(1 month)
  • 6 month infant % Muscle Mass(6 months)
  • 12 month infant % Muscle Mass(12 months)
  • 1 month Infant Resting Energy Expenditure (REE)(1 month)
  • 6 month Infant Resting Energy Expenditure (REE)(6 months)
  • 12 month Infant Resting Energy Expenditure (REE)(12 months)
  • 1 month Infant Neuromotor Assessment(1 month)
  • 6 month Infant Neuromotor Assessment(6 months)
  • 12 month Infant Neuromotor Assessment(12 months)
  • 1 month Infant Veggie Meter(1 month)
  • 6 month Infant Veggie Meter(6 months)
  • 12 month Infant Veggie Meter(12 months)
  • 1 month Infant Blood Biomarkers (CRP)(1 month)
  • 6 month Infant Blood Biomarkers (CRP)(6 months)
  • 12 month Infant Blood Biomarkers (CRP)(12 months)
  • 1 month Infant Blood Biomarkers (IL6)(1 month)
  • 6 month Infant Blood Biomarkers (IL6)(6 months)
  • 12 month Infant Blood Biomarkers (IL6)(12 months)
  • 1 month Infant Blood Biomarkers (adiponectin)(1 month)
  • 6 month Infant Blood Biomarkers (adiponectin)(6 months)
  • 12 month Infant Blood Biomarkers (adiponectin)(12 months)
  • 1 month Infant Metabolomics(1 month)
  • 6 month Infant Metabolomics(6 months)
  • 12 month Infant Metabolomics(12 months)
  • 16wk Maternal Resting Heart Rate(16wks gestation)
  • 36wk Maternal Resting Heart Rate(36wks gestation)
  • 1 month Postpartum Maternal Resting Heart Rate(1 month postpartum)
  • 6 month Postpartum Maternal Resting Heart Rate(6 months postpartum)
  • 12 month Postpartum Maternal Resting Heart Rate(12 months postpartum)
  • 16wk Maternal Resting Blood Pressure(16wks gestation)
  • 36wk Maternal Resting Blood Pressure(36wks gestation)
  • 1 month Postpartum Maternal Resting Blood Pressure(1 month postpartum)
  • 6 month Postpartum Maternal Resting Blood Pressure(6 months postpartum)
  • 36wk Maternal Body Fat %(36wks gestation)
  • 1 month Postpartum Maternal Body Fat %(1 month postpartum)
  • 6 month Postpartum Maternal Body Fat %(6 months postpartum)
  • 12 month Postpartum Maternal Body Fat %(12 months postpartum)
  • 16wk Maternal Biomarkers (CRP)(16wks gestation)
  • 36wk Maternal Biomarkers (CRP)(36wks gestation)
  • 1 month Postpartum Maternal Biomarkers (CRP)(1 month postpartum)
  • 6 month Postpartum Maternal Biomarkers (CRP)(6 months postpartum)
  • 12 month Postpartum Maternal Biomarkers (CRP)(12 months postpartum)
  • 16wk Maternal Biomarkers (IL6)(16wks gestation)
  • 36wk Maternal Biomarkers (IL6)(36wks gestation)
  • 1 month Postpartum Maternal Biomarkers (IL6)(1 month postpartum)
  • 6 month Postpartum Maternal Biomarkers (IL6)(6 months postpartum)
  • 12 month Postpartum Maternal Biomarkers (IL6)(12 months postpartum)
  • 16wks Maternal Biomarkers (adiponectin)(16wks gestation)
  • 36wks Maternal Biomarkers (adiponectin)(36wks gestation)
  • 1 month postpartum Maternal Biomarkers (adiponectin)(1 month postpartum)
  • 6 month postpartum Maternal Biomarkers (adiponectin)(6 months postpartum)
  • 12 month postpartum Maternal Biomarkers (adiponectin)(12 months postpartum)
  • 16wks Maternal Biomarkers (cortisol)(16wks gestation)
  • 36wks Maternal Biomarkers (cortisol)(36wks gestation)
  • 1 month Postpartum Maternal Biomarkers (cortisol)(1 month postpartum)
  • 6 month Postpartum Maternal Biomarkers (cortisol)(6 months postpartum)
  • 12 month Postpartum Maternal Biomarkers (cortisol)(12 months postpartum)

Study Sites (1)

Loading locations...

Similar Trials